| Xiangwei Wu, Ph.D. |
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Clinical Cancer Prevention - Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
1. Function of tumor suppressor p53.
2. Mechanisms of apoptosis and application in cancer treatment and prevention.
3. Novel pathways in stress reponse.
Office Address
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1013
Houston, TX 77030
Room Number: S7.8336A
Phone: (713) 745-2867
Fax: (713) 745-4230
1515 Holcombe Blvd.
Unit Number: 1013
Houston, TX 77030
Room Number: S7.8336A
Phone: (713) 745-2867
Fax: (713) 745-4230
Education & Training
Degree-Granting Education | |
| 1991 | Baylor College of Medicine, Houston, TX, PHD, Biochemistry |
| 1985 | Shanghai Institute of Organic Chemistry, Shanghai, China, MS, Graduate Student, Organic Chemistry |
| 1984 | Peking University, Beijing, China, BS, Chemistry |
Postgraduate Training | |
| 1992-1995 | Postdoctoral Fellowship, Department of Molecular Biology, Princeton University, Princeton, NJ |
Experience/Service
Academic Appointments
Associate Professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2006-8/2011
Administrative Appointments/Responsibilities
Director of Basic Science Research, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2011
Professional Memberships
| American Association for Cancer Research Member, 2009-present |
Selected Publications
Peer-Reviewed Original Research Articles | |
| 1. | Ren X, Xu Z, Myers JN, Wu, X. Bypass NFkappaB-Mediated Survival Pathways by TRAIL and Smac. Cancer Biol Ther 6(7):1031-5, 2007. PMID: 17611406. |
| 2. | Yang L, Deng YB, Wu, X. [Bcl-xl blocks tumor necrosis factor alpha-induced caspase 8 activation and apoptosis]. Zhonghua Gan Zang Bing Za Zhi. 13(4):286-9, 2005, 2005. PMCID: PMC15850519. |
| 3. | Deng, Y, Ren, X, Lin, Y., Yang, L., and Wu, X. A JNK-dependent pathway is required for TNFa-induced apoptosis. Cell 115:61-70, 2004. PMID: 14532003. |
| 4. | Deng Y., Lin, Y., and Wu, X. Trail Induced Apoptosis Requires Bax-Dependent Mitochondrial Release of Smac/DIABLO. Genes & Develop 16:33-45, 2002. |
| 5. | Deng, Y. and Wu, X. Peg3/Pw1 Promotes p53-Mediated Apoptosis by Inducing Bax Translocation from Cytosol to Mitochondria. Proc Natl Acad Sci USA 97(22):12050-12055, Oct. 24, 2000. PMCID: PMC11050235. |
Invited Articles | |
| 1. | Wu X, Patterson S, Hawk E. Chemoprevention - History and General Principles. Best Pract Res Clin Gastroenterol 25(4-5):445-59, 8/2011. PMID: 22122762. |
| 2. | Wu, X. and Bax, Y. Bax and BH3-Domain-Only Proteins in p53-mediated apoptosis. Frontiers in Bioscience 7:151-156, 2002. |
Editorials | |
| 1. | Wu X, Lippman SM. An intermittent approach for cancer chemoprevention. Nat Rev Cancer 11(12):879-85, 2011. e-Pub 11/2011. PMID: 22071977. |
Abstracts | |
| 1. | Zhang, L. Ren, X., Wen, XF., Wu, X. Chemoprevention of Colorectal Cancer by Targeting APC-Deficient Cells to Apoptosis. Frontiers in Cancer Prevention Research, 2008. |
Grant & Contract Support
| Title: | Induction of synthetic lethality in premalignant nutany K-ras cells in pancreas: chemoprevention of pancreatic cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Duration: | 9/2013 - 10/2015 |
| Title: | Plasmonic nanobubbles as nanotherpeutic agents for combinatorial treatment of supperficial drug-resistant cancers |
| Funding Source: | National Science Foundation (NSF) |
| Role: | Co-Principal Investigator |
| Principal Investigator: | Dmitri Lapotko |
| Duration: | 8/2013 - 7/2015 |
| Title: | Theranostics of squamous cell carcinoma with plasmonic nanobubbles |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Principal Investigator |
| Principal Investigator: | Dmitri Lapotko |
| Duration: | 5/2013 - 4/2016 |
| Title: | Guided intercellular drug delivery technology for treatment of heterogeneous and drug-resistant targets |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Principal Investigator: | Dmitri Lapotko |
| Duration: | 7/2012 - 6/2017 |
| Title: | Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Duration: | 12/1/2011 - 11/30/2014 |
| Title: | Chemoprevention of pancreatic cancer by induction of synthetic lethality in mutant K-ras cells |
| Funding Source: | Duncan Family Institute |
| Role: | Principal Investigator |
| Duration: | 9/1/2011 - 8/31/2013 |
| Title: | A Therapeutic Approach for Lung Cancer Chemoprevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Duration: | 12/1/2010 - 11/30/2013 |
| Title: | Regulation of TNFa Response |
| Funding Source: | NIH/NIAID |
| Role: | Principal Investigator-MDACC |
| Duration: | 12/15/2004 - 11/30/2010 |
Last updated: 3/1/2013
- Global Navigation
- About Us
- Locations
- Calendar
- Careers
- Publications
- How You Can Help
- Contact Us
- Newsroom
- Site Index
- Patient and Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children's Cancer Hospital
- Services & Amenities
- Education and Research
- Departments, Programs and Labs
- PeopleFinder
- Research at MD Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Alert Information
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates
- Legal and Policy
- Legal Statements
- Site Policies
- Reporting Fraud, Waste & Abuse
© 2010 The University of Texas M. D. Anderson Cancer Center

